Coexpression, prognostic significance and predictive value of EGFR, EGFRvIII and phosphorylated EGFR in colorectal cancer

International Journal of Oncology

Volumn 27, Issue 2, 2005, Pages 317-325

  Cunningham, Matthew P ^a   Essapen, Sharadah ^b   Thomas, Hilary ^a,b   Green, Margaret ^c   Lovell, David P ^a   Topham, Clare ^b   Marks, Christopher ^d   Modjtahedi, Helmout ^a  

^a UNIVERSITY OF SURREY   (United Kingdom)

^b St Luke's Cancer Centre   (United Kingdom)

^c Department of Histopathology ^*  (United Kingdom)

^d ROYAL SURREY COUNTY HOSPITAL   (United Kingdom)

Author keywords

Colorectal; EGFR; EGFRvIII; PEGFR; Prognosis; Radio therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR VIII;

AGED; ANTIBODY SPECIFICITY; ARTICLE; BIOSYNTHESIS; CANCER STAGING; COLORECTAL TUMOR; COMPARATIVE STUDY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PHOSPHORYLATION; PREDICTION AND FORECASTING; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL; TUMOR CELL LINE;

AGED; ANTIBODY SPECIFICITY; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PHOSPHORYLATION; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 33644677317     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.27.2.317     Document Type: Article

References (50)

1. Walker J and Quirkc P: Prognosis and response to therapy in colorectal cancer. Eur J Cancer 38: 880-886. 2(X)2.
2. Jemal A. Tiwari RC. Murray T. Ghafoor A. Samuels A. Ward E. Feuer EJ and Thun MJ: Cancer statistics 2004. CA Cancer J Clin 54: 8-29. 2004.
3. Harris AL and Neal DE: Epidermal growth factor and its receptor in human cancer. In: Growth Factors and Oncogenes in Breast Cancer. Sluyser M red). Ellis Horwood Ltd.. Chichester. pp60-90. 1987.
4. Gullick WG: Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 47: 87-98. 1991.
5. Modjtahedi H and Dean C: The receptor for EGF and its ligands: expression, prognostic value and target for therapy in cancer. Int J Oncol 4: 277-296. 1994.
6. Salomon DS. Bradt R. Ciardiello F and Normano N: Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19: 183-232. 1995.
7. Nicholson RI. Gee JMW and Harper ME; EGFR and cancer prognosis. Eur J Cancer 37: 9-15. 2001.
8. Herbst RS: Review of epidermal growth factor receptor biology. Int J Radial Oncol Biol Phys 59: 21-26. 2004.
9. Mendelsohn J and Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21: 2787-2799. 2(X)3.
10. Ochs JS: Rationale and clinical basis for combining gefitinib (IRESSA ZD 1839) with radiation therapy for solid tumours. Int J Radial Oncol Biol Phys 58: 941-949. 2004.
11. Magnusson I. Rosen AV. Nilsson R. Macias A. Perez R and Skoog L: Receptors for epidermal growth factor and sex steroid hormones in human colorectal carcinomas. Anticancer Res 9: 299-302. 1989.
12. Steele RJ. Kelly P. Ellul B and Eremin O: Epidermal growth factor receptor expression in colorectal cancer. Br J Surg 77: 1352-1354. 1990.
13. Moorghen M. Ince P. Finney KJ. Watson AJ and Harris AL: Epidermal growth factor receptors in colorectal carcinoma. Anticancer Res 10: 605-612. 1990.
14. Mayer A. Takimoto M. Fritz E. Schllander G. Kofler K and Ludwig H: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal cancers. Cancer 71: 2454-2460. 1993.
15. Hayashi Y. Widjono YW. Ohta K. Hanioka K. Obayashi C. Itoh K. Imai Y and Itoh H: Expression of EGF. EGF-receptor. p53, v-erb B and ras p21 in colorectal neoplasms by immuno-staining paraffin-embedded tissues. Pathol Int 44: 124-130. 1994.
16. Goldstein NS and Armin M: Epidermal growth factor receptor immunohistochemical reactivity in patients with American Joint Committee on Cancer Stage IV colon adenocarcinoma: implications for a standardized scoring system. Cancer 92: 1331-1346. 2001.
17. McKay JA. Murray LJ. Curran S. Ross VG. Clark C. Murray GI. Cassidy J and McLeod HL: Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases. Eur J Cancer 38: 2258-2264. 2002.
18. Khorana AA. Rayan CK. Cox C. Eberly S and Sahasrabudhe DM; Vascular endothelial growth factor. CD86. and epidermal growth factor receptor expression and survival in patients with stage II and stage III colon carcinoma. Cancer 97: 960-968, 2003.
19. Kopp R. Rothbauer E, Mueller E. Schildberg FW, Jauch KW and Pfeiffer A: Reduced survival of rectal cancer patients with increased tumour epidermal growth factor receptor levels. Dis Colon Rectum 6: 1391-1399, 2003.
20. Spano J-P, Lagorce C, Allan D, et al: Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol 16: 102-108.2005.
21. Ciardiello F and Tortora G: Epidermal growth factor receptor (EGFR) as a target in cancer therapy: understanding the role of receptor expression and other molecular determinants that could influence the response to anti-EGFR drugs. Eur J Cancer 3: 1348-1354. 2003.
22. Atkins D. Reiffen KA., Tegtmeier CL, Winther H. Bonato MS and Storkel S: Immunohistochemical detection of EGFR in paraffin-embedded tumour tissues: variation due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52: 893-901.2004.
23. Bigner SH. Humphrey PA. Wong AJ. Vogelstcin B, Mark J. Friedman HS and Bigner DD: Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. Cancer Res 50: 8017-8022, 1990.
24. Pedersen MW, Meltorn M. Damstrup L and Poulsen HS: The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann Oncol 12:745-760, 2001.
25. Paez JG. Janne PA. Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500. 2004.
26. Moscatello DK, Montgomery RB, Sundareshan P. McDanel H. Wong MY and Wong AJ: Transformation and altered signal transduction by a naturally occurring mutant EGF receptor. Oncogene 13: 85-96. 1996.
27. Moscatello DK. Holgado-Madruga M, Godwin AK, et al: Frequent expression of a mutant epidermal growth factor receptor in multiple human tumours. Cancer Res 55: 5536-5539, 1995.
28. Olapade-Olaopa EO. Moscatello DK. MacKay EH. Horsburgh T, Sandhu DPS, Terry TR, Wong AJ and Habib FK: Evidence for the differential expression of a variant EGF receptor protein in human prostate cancer. Br J Cancer 82: 186-194. 2000.
29. Modjtahcdi H, Styles JM and Dean CJ: The human EGF receptor as a target for cancer therapy: six new rat mAbs against the receptor on the breast carcinoma MDA-MB 468. Br J Cancer 67: 247-253, 1993.
30. Essapen S. Thomas H. Green M. De Vries C. Cook MG. Marks C, Topham C and Modjtahedi H: The expression and prognostic significance of HER-2 in colorectal cancer and its relationship with clinicopathological parameters. Int J Oncol 24: 241-248, 2004.
31. Modjtahedi H. Moscatello DK. Box G, et al: Targeting of cells expressing wild-type EGFR and type-ill mutant EGFR (EGFRvlII) by anti-EGFR mAb ICR62: a two-pronged attack for tumour therapy. Int J Cancer 105: 273-280, 2003.
32. Jacot W, Pujol JL, Boher JM and Lamy PJ: Serum EGF-receptor and HER-2 extracellular domains and prognosis of non-small-cell lung cancer. Br J Cancer 91: 430-433, 2004.
33. Fric P. Sovova V, Sloncova E, Lojda Z. Jirasek A and Cermak J: Different expression of some molecular markers in sporadic cancer of the left and right colon. Eur J Cancer Prev 9: 265-268. 2000.
34. Nakae S. Shimada E and Urakawa T: Study of c-erb B-2 protein and epidermal growth factor receptor expression and DNA ploidy pattern in colorectal carcinoma. J Surg Oncol 54: 246-251. 1993.
35. Lee JC. Wang S-T. Chow N-H and Yang HB: Investigation of the prognostic value of coexpressed erbB family members for the survival of colorectal cancer patients after curative surgery. Eur J Cancer 38: 1065-1071. 2002.
36. Scartozzi M. Bearzi I. Berardi R, Mandolesi A. Fabris G and Cascinu S: Epidermal growth factor receptor (EGFR) status in primary colorectal tumours does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 22: 4720-4726. 2004.
37. Ekstrand AJ. Liu L. He J. Hamid ML. Longo N. Collins VP and James CDl: Altered subcellular location of an activated and tumour-associated epidermal growth factor receptor. Oncogene 10: 1455-1460. 1995.
38. Ge H. Gong X and Tang CK: Evidence of high incidence of EGFRvlII expression and coexpression with EGFR in human invasive breast cancer by laser capture microdissection and immunohistochemical analysis. Int J Cancer 98: 357-361, 2002.
39. Kanemalsu T. Yano S. Uehara H. Bando Y and Sone S: Phosphorylation, but not overexpression. of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. Oncol Res 13: 289-298, 2003.
40. Okamoto I. Kenyon LC. Emlet DR. et al: Expression of constitutively activated EGFRvlII in non-small cell lung cancer. Cancer Sci 94: 50-56. 2003.
41. Kallio JP, Hirvikoski P. Helin H. Kellokumpu-Lehtinen P. Luukkaala T. Tammela TLJ and Martikainen PM: Membranous location of EGFR immunostaining is associated with good prognosis in renal cell carcinoma. Br J Cancer 89: 1266-1269, 2003.
42. Giralt J. Eraso A. Armengol M. Rosello J. Majo J, Ares C, Espin E. Benavente S and De Torres I: Epidermal growth factor receptor is a predictor of tumour response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radial Oncol Biol Phys 54: 1460-1465. 2002.
43. Lammering G. Hewit TH. Valerie K, Contessa JN. Amorino GP, Dent P and Schmidt-Ullrich RK: EGFRvIII-mediated radio-resistance through a strong cytoprotective response. Oncogene 22: 5545-5553. 2003.
44. Lin SY. Makino K. Xia E. et al: Nuclear localisation of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3: 802-808. 2001.
45. Lo HW. Xia W. Wei Y. et al: Novel prognostic value of nuclear epidermal growth factor receptor in breast cancer. Cancer Res 65: 338-348. 2005.
46. Baselga J: Combining the anti-EGFR agent gefitinib with chemotherapy in non-small cell lung cancer: how do we go from INTACT to impact? J Clin Oncol 22: 759-761.2004.
47. Cunningham D, Humblet Y. Siena S, et al: Cotuximab monotherapy and cotuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351: 337-345. 2004.
48. Dancey J: Epidermal growth factor receptor inhibitors in clinical development. Int J Radial Oncol Biol Phys 58: 1003-1007, 2004.
49. Scharg D: The price tag on progress. N Engl J Med 351: 317-319, 2004.
50. Modjtahedi H: Molecular therapy of head and neck cancer. Cancer Metastasis Rev 24: 129-146, 2005.